Evotec (EVO) Expected to Announce Quarterly Earnings on Wednesday

Key Points

• Evotec is expected to announce its quarterly earnings before the market opens on August 13th, with analysts predicting a loss of ($0.12) per share and revenue of $202.02 million.
• The company's stock recently rose by 1.3% to $3.80, although its trading volume was significantly below the average.
• A hedge fund, Bank of America Corp DE, significantly increased its stake in Evotec by 262.5% in the fourth quarter, now owning approximately 12,828 shares.

Evotec (NASDAQ:EVO - Get Free Report) will likely be releasing its earnings data before the market opens on Wednesday, August 13th. Analysts expect Evotec to post earnings of ($0.12) per share and revenue of $202.02 million for the quarter.

Evotec Stock Up 1.3%

Evotec stock traded up $0.05 during trading on Thursday, hitting $3.80. The company had a trading volume of 8,249 shares, compared to its average volume of 98,946. The company has a quick ratio of 1.93, a current ratio of 2.03 and a debt-to-equity ratio of 0.46. Evotec has a 1-year low of $2.84 and a 1-year high of $5.64. The company's 50 day simple moving average is $4.08 and its 200-day simple moving average is $3.99.

Institutional Investors Weigh In On Evotec

A hedge fund recently raised its stake in Evotec stock. Bank of America Corp DE raised its position in Evotec AG (NASDAQ:EVO - Free Report) by 262.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,828 shares of the company's stock after acquiring an additional 9,289 shares during the quarter. Bank of America Corp DE's holdings in Evotec were worth $53,000 as of its most recent SEC filing. 5.81% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on EVO shares. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Evotec in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft upgraded shares of Evotec from a "sell" rating to a "hold" rating in a report on Thursday, April 24th.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.